Short answer
RxSight, Inc. (RXST) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M (down 19.1% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $25M
- −19.1% YoY · −9.9% QoQ
- Net income
- −$16M
- −65.3% YoY · −34.1% QoQ
- Operating margin
- -75.4%
- EPS (diluted)
- −$0.39
- −62.5% YoY · −30.0% QoQ
Source: XBRL data from the RxSight, Inc. (RXST) Q3 2026 10-Q on SEC EDGAR. USD.
RxSight, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $24.6M, down 19.0% YoY from $30.3M, amid increased IOL competition
- Product gross margin 73.6% vs 79.9% YoY, pressured by inventory reserves and higher-cost inventory
- LAL sales $22.8M vs $25.7M YoY, while LDD sales fell to $3.2M from $4.1M
- Cash, equivalents and short-term investments $254.7M; operating cash flow $24.8M vs $(14.4)M YoY
- Near-term outlook: renewed revenue growth expected from commercial realignment, with competitive trialing and excess LDD inventory as headwinds
Risk Factors
- New risk from June 2026 Alcon collaboration: $70M feasibility and $40M approval milestones remain optional and contingent
- Most material update: LDD manufacturing paused in Q3 2026 after declining sales, creating inventory write-down and margin risks
- Regulatory risk: QMSR became effective February 2026, requiring compliant manufacturing processes for continued commercialization
- Near-term market risk: sales declined through Q3 2026, while premium LAL demand remains sensitive to patient out-of-pocket spending
- Financial risk: $254.7M cash, equivalents and short-term investments held with one financial institution as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RxSight, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.